Professor | Jia Bei Wang | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Jia Bei Wang
Contact Information	jbwang16@ustc.edu.cn
Language ability	Chinese, English
Province	Anhui

Upload Avatar (500 x 500)

Name

Jia Bei Wang

Contact Information

jbwang16@ustc.edu.cn

Language ability

Chinese, English

Province

Anhui

University/Lab Affiliation and Title	University of Science and Technology of China
Faculty	Mayo Clinic College of Medicine
Academic Background & Achievements	2008.09-2011.07 Doctorate: Harbin Medical University 2005.09-2008.07 Master's: Harbin Medical University 1999.09-2004.07 Bachelor's: Harbin Medical University Published over 50 SCI-indexed papers Selected for National Youth Talent Program Received Education Ministry's Natural Science First Prize
Awards	Anhui Province 'Special Support Plan' Innovative Leading Talent (2019): Awarded by Anhui Provincial Government Anhui Province Academic and Technical Leader Reserve Candidate (2019): Awarded by Anhui Provincial Government Anhui Government Special Allowance (2020): Awarded by Anhui Provincial Government Anhui Province Natural Science Foundation Outstanding Youth Fund Recipient (2022): Awarded by Anhui Science and Technology Department Anhui Province Health and Wellness Backbone Talent (2022): Awarded by Anhui Health and Wellness Committee Anhui Province Outstanding Young Graduate Mentor (2022): Awarded by Anhui Education Department Changjiang Scholars Program Young Scholar (2024): Awarded by Ministry of Education

University/Lab Affiliation and Title

University of Science and Technology of China

Faculty

Mayo Clinic College of Medicine

Academic Background & Achievements

2008.09-2011.07 Doctorate: Harbin Medical University
2005.09-2008.07 Master's: Harbin Medical University
1999.09-2004.07 Bachelor's: Harbin Medical University
Published over 50 SCI-indexed papers
Selected for National Youth Talent Program
Received Education Ministry's Natural Science First Prize

Awards

Anhui Province 'Special Support Plan' Innovative Leading Talent (2019): Awarded by Anhui Provincial Government
Anhui Province Academic and Technical Leader Reserve Candidate (2019): Awarded by Anhui Provincial Government
Anhui Government Special Allowance (2020): Awarded by Anhui Provincial Government
Anhui Province Natural Science Foundation Outstanding Youth Fund Recipient (2022): Awarded by Anhui Science and Technology Department
Anhui Province Health and Wellness Backbone Talent (2022): Awarded by Anhui Health and Wellness Committee
Anhui Province Outstanding Young Graduate Mentor (2022): Awarded by Anhui Education Department
Changjiang Scholars Program Young Scholar (2024): Awarded by Ministry of Education

Areas of Focus	Pathogenesis, metabolism, immune microenvironment, targeted therapy, and drug resistance reversal of hepatobiliary tumors
Publications	LncRNA CRNDE Drives the Progression of Hepatocellular Carcinoma by inducing the Immunosuppressive Niche, Li X, Liang S, Fei M, Ma K, Sun L, Liu Y, Liu L, Wang J., 2024 LncRNA PWRN1 inhibits the progression of hepatocellular carcinoma by activating PKM2 activity, Fei M, Li X, Liang S, Zhou S, Wu H, Sun L, Liu Y, Hu Q, Liu L, Wang J., 2024 Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy, Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S, Sun L, Liu Y, Du Y, Guo X, Cui T, Zhou H, Wang J, Yin D, Song R, Zhang S, Cai W, Meng F, Guo H, Zhang B, Yang D, Bao R, Hu Q, Wang J, Ye Y, Liu L., 2023 Donafenib and GSK-J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression, Zheng C, Zhang B, Li Y, Liu K, Wei W, Liang S, Guo H, Ma K, Liu Y, Wang J, Liu L., 2023 Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib, Liu Y, Sun L, Guo H, Zhou S, Wang C, Ji C, Meng F, Liang S, Zhang B, Yuan Y, Ma K, Li X, Guo X, Cui T, Zhang N, Wang J, Liu Y, Liu L., 2023 UBE2O reduces the effectiveness of interferon-α via degradation of IFIT3 in hepatocellular carcinoma, Li H, Liu Y, Cheng C, Wu Y, Liang SH, Wu L, Wang H, Tu CY, Yao HH, Meng FZ, Zhang B, Wang W, Wang JB, Liu LX., 2023 Cytochrome B5 type A alleviates HCC metastasis via regulating STOML2 related autophagy and promoting sensitivity to ruxolitinib, Guo H, Liang S, Wang Y, Zhou S, Yin D, Zhang S, Wang J, Wu D, Ma K, Liu Y, Sun L, Ji C, Li X, Zhou H, Yang G, Guo X, Cui T, Li Z, Liu Y, Wang J, Liu L., 2022 A PLCB1-PI3K-AKT signaling axis activates EMT to promote cholangiocarcinoma progression, Liang S, Guo H, Ma K, Li X, Wu D, Wang Y, Wang W, Zhang S, Cui Y, Liu Y, Sun L, Zhang B, Xin M, Zhang N, Zhou H, Liu Y, Wang J, Liu L., 2021

Areas of Focus

Pathogenesis, metabolism, immune microenvironment, targeted therapy, and drug resistance reversal of hepatobiliary tumors

Publications

LncRNA CRNDE Drives the Progression of Hepatocellular Carcinoma by inducing the Immunosuppressive Niche, Li X, Liang S, Fei M, Ma K, Sun L, Liu Y, Liu L, Wang J., 2024
LncRNA PWRN1 inhibits the progression of hepatocellular carcinoma by activating PKM2 activity, Fei M, Li X, Liang S, Zhou S, Wu H, Sun L, Liu Y, Hu Q, Liu L, Wang J., 2024
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy, Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S, Sun L, Liu Y, Du Y, Guo X, Cui T, Zhou H, Wang J, Yin D, Song R, Zhang S, Cai W, Meng F, Guo H, Zhang B, Yang D, Bao R, Hu Q, Wang J, Ye Y, Liu L., 2023
Donafenib and GSK-J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression, Zheng C, Zhang B, Li Y, Liu K, Wei W, Liang S, Guo H, Ma K, Liu Y, Wang J, Liu L., 2023
Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib, Liu Y, Sun L, Guo H, Zhou S, Wang C, Ji C, Meng F, Liang S, Zhang B, Yuan Y, Ma K, Li X, Guo X, Cui T, Zhang N, Wang J, Liu Y, Liu L., 2023
UBE2O reduces the effectiveness of interferon-α via degradation of IFIT3 in hepatocellular carcinoma, Li H, Liu Y, Cheng C, Wu Y, Liang SH, Wu L, Wang H, Tu CY, Yao HH, Meng FZ, Zhang B, Wang W, Wang JB, Liu LX., 2023
Cytochrome B5 type A alleviates HCC metastasis via regulating STOML2 related autophagy and promoting sensitivity to ruxolitinib, Guo H, Liang S, Wang Y, Zhou S, Yin D, Zhang S, Wang J, Wu D, Ma K, Liu Y, Sun L, Ji C, Li X, Zhou H, Yang G, Guo X, Cui T, Li Z, Liu Y, Wang J, Liu L., 2022
A PLCB1-PI3K-AKT signaling axis activates EMT to promote cholangiocarcinoma progression, Liang S, Guo H, Ma K, Li X, Wu D, Wang Y, Wang W, Zhang S, Cui Y, Liu Y, Sun L, Zhang B, Xin M, Zhang N, Zhou H, Liu Y, Wang J, Liu L., 2021

Pathogenesis Metabolism Immune Microenvironment Targeted Therapy Drug Resistance Hepatobiliary Tumors Cancer Research Clinical Diagnosis Basic Research Oncology

Shandong Ye - University of Science and Technology of China

Weidong Jia - University of Science and Technology of China

Wenbin Liu - University of Science and Technology of China

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us